Actuate Therapeutics' elraglusib enters BEACON2 neuroblastoma trial
Actuate Therapeutics has announced that its GSK-3β inhibitor elraglusib has been selected for evaluation in BEACON2, a Cancer Research UK-sponsored multi-arm, multi-stage Phase 1/2 platform trial targeting relapsed and refractory neuroblastoma in children. The selection marks a significant step for the NASDAQ-listed company's lead programme and extends its clinical footprint into a high-profile European academic trial network.
Under the BEACON2 protocol, elraglusib will be combined with dinutuximab beta — an anti-GD2 immunotherapy — plus a chemotherapy backbone. The trial will first enrol up to 20 patients in a dose confirmation cohort to establish safety parameters, the maximum tolerated dose, recommended Phase 2 dose, and pharmacokinetic profile. If that stage is completed successfully, the combination will advance into a randomised portion of the trial enrolling approximately 75 patients, with a planned interim analysis built into the design.
Scientific rationale
The mechanistic case for elraglusib in neuroblastoma centres on GSK-3β's role in MYCN-driven disease biology. MYCN amplification is one of the strongest prognostic markers in high-risk neuroblastoma, and preclinical work cited by Actuate suggests GSK-3β inhibition suppresses tumour cell proliferation, promotes apoptosis, and potentiates both chemotherapy and anti-GD2 immunotherapy. In Th-MYCN mouse models, 60% of animals treated with elraglusib combined with temozolomide/irinotecan and the anti-GD2 antibody 14G2a remained tumour-free at one year, compared with none in the chemotherapy-only arm. Increased infiltration of CD4+, CD8+, and NK cells in the tumour microenvironment suggested a meaningful immunomodulatory contribution alongside the direct anti-tumour effect.
Clinical signals have followed. In an ongoing Phase 1/2 study (NCT04239092) combining elraglusib with cyclophosphamide and topotecan in heavily pre-treated paediatric patients, one neuroblastoma patient with a high-risk molecular profile achieved a complete bone marrow response within nine cycles. Elraglusib also holds FDA Rare Pediatric Disease designation for the indication, which carries the potential for a priority review voucher on approval — a commercially significant asset given voucher values have historically traded in the region of $100 million.
Market and competitive context
BEACON2 builds on the original BEACON trial (2012–2021), which enrolled 225 patients across Europe and remains the largest randomised study ever conducted in relapsed and refractory neuroblastoma. That trial identified two combinations — irinotecan/temozolomide and dinutuximab beta with chemotherapy — as worthy of further development, with one-year progression-free survival rates of 65% and 49% respectively. BEACON2 is designed to test new arms against this established backbone, giving selected drugs access to a rigorous comparative dataset rather than a single-arm study.
The relapsed/refractory neuroblastoma space remains one of paediatric oncology's most challenging and commercially thin segments. Frontline regimens have improved, but post-relapse options are narrow, and few agents have achieved regulatory approval beyond dinutuximab beta itself. Actuate is one of a small number of clinical-stage companies exploring novel mechanisms in the indication; others have pursued DFMO-based maintenance, ALK inhibitors, and checkpoint immunotherapy, though none has yet transformed the post-relapse prognosis materially.
One notable caveat: Actuate's forward-looking disclosures state that the company requires additional capital beyond July 2026 to continue operations, raising going-concern questions that the company's investors will need to weigh against the clinical momentum generated by the BEACON2 selection. Daniel Schmitt, president and chief executive, described the inclusion as "a defining milestone for the elraglusib program," and framed the CRCTU sponsorship as a capital-efficient route to generating meaningful late-stage data. Whether Actuate can secure the necessary financing to remain a full participant through the trial's randomised phase remains the most pressing near-term question for the programme.